MiMedx Q2 revenue $87M (+7% YoY), GAAP EPS $0.12, Adjusted EBITDA margin 23%

MIMEDX GROUP, INC.

2024-Q2 EPS reported $0.18 revenue$171,915,000

Net sales $87M, up 7% YoY; GAAP net income $18M, EPS $0.12.
Adjusted EBITDA $20M, margin 23% vs 17.4% in Q2 2023.
CEO reports competitive pressure from high-priced skin substitutes causing employee and customer attrition.
Launched HELIOGEN (first xenograft) and commenced RCT for EPIEFFECT.
Cash $69M; 2024 net sales growth guided to mid-to-high single digits.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.